A group of hemophilia patients is calling on the US FDA to respond to a patent dispute that could prevent patient access to Genentech Inc.'s Hemlibra (emicizumab-kxwh).
They ask the agency to hold a public hearing to examine the effects of Shire PLC's request for a...





